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Available online 27 September 2016AbstractObjectives: We aim to elucidate the clinical outcomes of bisphosphonate-associated atypical femoral fracture and the clinical results depending
on the bisphosphonate therapy period.
Methods: Twenty cases involving 15 patients who had been diagnosed with atypical femoral facture between 2004 and 2014 and who had been
followed up for at least 12 months were retrospectively analyzed. The control group was composed of 15 typical femoral facture patients. We
used plain radiography and physical examinations to determine the period of time required for fracture healing as well as complication
occurrence. We investigated the bisphosphonate administration status and duration and the names of its components, bilateral fracture occur-
rence status, the period of time required for bone union, and reoperation or bone graft status due to nonunion.
Results: Revision surgery involving a bone graft was performed due to nonunion in 1 out of 15 cases. Except in one revision case, the duration of
the union was 11.9 months on average in 14 cases of atypical fracture patients, and 4.3 months on average in the control group. This difference
was statistically significant (p < 0.05). The bisphosphonate administration duration was positively correlated with the union period (p < 0.05). In
contrast, there was no statistically significant correlation between the bisphosphonate administration duration and the incidence of bilateral
atypical fractures (p > 0.05).
Conclusions: Atypical femoral fractures required more time for bone union than typical ones and prolonged bisphosphonate administration led to
a longer period of time required for bone union.
© 2016 The Korean Society of Osteoporosis. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Typical femoral fractures usually do not occur in the sub-
trochanteric area and comminuted fracture patterns appear in
many cases. Conversely, atypical femoral fractures are rela-
tively more commonly found in the subtrochanteric area with
specific features [1]. Atypical femoral fractures are primarily
characterized by transverse or exhibit short oblique fracture
configurations, non-comminuted fracture patterns, medial* Corresponding author. Department of Orthopedic Surgery, College of
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).spikes, localized periosteal thickening of the lateral cortex,
generalized thickening of the femoral cortices, and confer
prodromal symptoms such as pain [2e4] (Fig. 1).
The American Society for Bone and Mineral Research
(ASBMR) task force established major and minor features of
atypical femoral fractures and classified them into complete
and incomplete categories [5]. Although these criteria are of
great help in understanding atypical femoral fractures, some
features are still controversial.
While bisphosphonate is commonly used to prevent oste-
oporotic fractures, many researchers have recently reported
atypical femoral fractures without trauma or following mild
trauma among the patients who have been administered
bisphosphonate for extended periods of time [5e7]. However,
it is actually difficult to conduct research on the associationlsevier B.V. This is an open access article under the CC BY-NC-ND license
Fig. 1. Radiographs of the atypical femoral fracture. (A, B) shows atypical femoral fracture in femoral shaft region, and (C) in the subtrochanteric area. The
radiographic features of atypical femoral fractures: (1) medial spike; (2) transverse fracture pattern (3) localized periosteal thickening of the lateral cortex; (4)
generalized thickening of the femoral cortices.
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which occur very infrequently. The direct associations be-
tween atypical fractures are still controversial and the definite
cause of atypical femoral fractures is unknown.
This study aimed to determine the period of time required
for bone union in atypical femoral fractures associated with
bisphosphonate, evaluate their prognoses and determine the
association between the bisphosphonate administration dura-
tion and the prognoses.
2. Subjects and methods2.1. Study populationTwenty cases involving 15 patients who had been diag-
nosed with an atypical femoral fracture between 2004 andTable 1
Demographics of 15 patients of atypical femur fracture.
Case Age Sex BMI Injury mode BMD Fra
Femur Spine
1 74 F 23.12 Slip down 2 2.3 Sha
2 58 F 24.97 Slip down 2.3 1.6 Sub
3 61 F 22.96 Slip down 3.2 2.8 Sub
4 73 F 19.98 Slip down 0.6 1.7 Sub
5 73 F 28.99 Slip down 3.1 4.2 Sub
6 70 F 22.27 Slip down 3.6 2.6 Sha
7 85 F 24.73 Slip down 2.4 2.7 Sha
8 85 F 26.84 Slip down 0.9 0.9 Sub
9 103 F 24.89 Slip down 4.4 3.9 Sha
10 85 F 26.49 Slip down 0.5 4.2 Sub
11 85 F 20.41 Slip down 4.3 5.7 Sha
12 84 F 19.98 Slip down () Sha
13 85 F 18.75 Slip down 4.4 4.7 Sha
14 89 F 16.80 Slip down () Sha
15 58 F 27.06 Slip down 0.6 0.6 Sub2014 and who had been followed for at least 12 months, were
retrospectively analyzed (Table 1). The control group was
composed of 15 typical femoral fracture patients, taking into
account gender, age, injury sites, BMI, fracture patterns, and
surgical procedures. The patients with underlying disease,
which could possibly affect bone union, were excluded from
the control group. In 5 out of 15 cases of atypical femoral
fractures, bilateral atypical femoral fractures were found.
A case in which an atypical fracture occurred seven years
after a typical fracture on the other side was included in the
control group.2.2. MethodsWe used plain radiography and physical examinations to
determine the period of time required for fracture healing ascture type Used nail Medication periods Union periods
ft Sirus nail 80 8
trochanter Long Gamma nail 67 6
trochanter PFNA 127 30
trochanter Long Gamma nail 79 9
trochanter PFNA 84 17
ft A2FN 12 5
ft ITST 38 4
trochanter Long Gamma nail 135 34
ft Sirus nail 89 9
trochanter PFNA () 10
ft M/DN recon nail 58 6
ft Plate & screws () 8
ft CFN 31 8
ft A2FN 78 16
trochanter Long PFNA () 20
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lateral radiographs of the fracture site showed that bone con-
tinuity was maintained or that ossification of the callus
covered at least three-fourths of the fracture plane and when
the fracture site involved no pressure pain or movement, it was
defined as a bone union. We investigated the bisphosphonate
administration status and duration and the names of its com-
ponents, bilateral fracture occurrence status, the period of time
required for bone union, and reoperation or bone graft status
due to nonunion.2.3. Statistical analysisFig. 2. Correlation of medication period and union period in atypical femoral
fracture cases.An SPSS 22.0 program was used to perform a paired t-test
and correlation analysis at the p < 0.05 significance level.
3. Results
The mean age of the atypical fracture patients was 77.9
(58e103 years) years. The mean follow up period was 15.3
months (12e34 months). Of the 15 patients, 7 patients showed
subtrochanteric fractures, and in 8 patients femoral shafts were
involved. Twelve of 15 patients had a history of bisphospho-
nate administration. Of the 3 patients without bisphosphonate
administration, 1 had multiple myeloma, 1 was using metho-
trexate (MTX) for rheumatoid arthritis, and 1 had no history of
specific conditions or medication. As for bisphosphonate,
alendronate was used in 10 cases and risedronate in 2 cases.
Revision surgery involving a bone graft was performed due to
nonunion in 1 out of 15 cases. Except in one revision case, the
duration of the union was 11.9 months on average in 14 cases
of atypical fracture patients, and 4.3 months on average in the
control group. This difference was statistically significant
(p < 0.05) (Table 2).
In 2 out of 5 cases of bilateral atypical femoral fractures,
both an atypical complete fracture on one side and an atypical
incomplete fracture on the other side were found at the same
time. Of these, one case involved bilateral femoral intra-
medullary nailing and the other was followed up because no
clinical symptom of an incomplete fracture was found. In the
other 2 cases, preventive intramedullary nailing was per-
formed for the incomplete fracture on the other side, which
was found three months and two years after the surgical
treatment for an atypical complete fracture, respectively. In 1
case, surgical treatment was performed for an atypical com-
plete femoral shaft fracture seven years after an atypical
fracture had occurred on the other femoral shaft.Table 2
Comparison of average union periods in Group A and B.
Group A (n ¼ 15) Group B (n ¼ 15) P-value
Union periods
(months)
11.93 ± 8.16 4.27 ± 1.98 0.008
Group A: Atypical fracture, Group B: Typical fracture (Values were presented
as Mean ± S.D.).The mean bisphosphonate administration duration was 73
months (12e135 months). The bisphosphonate administra-
tion duration was positively correlated with the union period
(p < 0.05) (Fig. 2). In contrast, there was no statistically
significant correlation between the bisphosphonate adminis-
tration duration and the incidence of bilateral atypical frac-
tures (p > 0.05).Fig. 3. Hip AP view shows complete fracture of left subtrochanter and
incomplete fracture (white arrow) of right subtrochanter (A). Immediate
postoperative radiography (B).
Fig. 4. Pre-operative radiography of a 58-year-old woman who had taken oral alendronate medication for 78 months prior to an atypical femoral subtrochantric
fracture (A). Immediate postoperative radiography (B). At six months after first operation, non-union of the fracture was noticed. An allo bone graft was performed
(C). At five months after the second operation, nonunion with metal failure was found (D). Immediately metal was removed and ORIF with long PFNA was
performed. A bone graft was done with femoral allobone (E). Union of the fracture was obtained 8 months after the third operation (F).
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With an increasingly aging population, the use of anti-
osteoporotic agents is on a gradual increase and atypical
femoral fractures related to bisphosphonate administration are
being reported. Now many researchers show that prolonged
bisphosphonate administration may lead to a higher incidence
of atypical femoral fractures.
The atypical femoral fracture group required statistically
significantly more time for bone union than the typical femoral
fracture group. While many researchers report the same result,
the definite cause of which has not yet been found, impaired
osteogenesis related to a severely suppressed bone turnover is
seemingly associated with atypical femoral fractures or
delayed union, taking into account a lower bone turnover rateand impaired osteogenesis among the patients administered
with bisphosphonate [2,8].
The bisphosphonate administration duration was found to
be positively correlated with the union period in the cases of
atypical fractures. Therefore, since prolonged bisphosphonate
administration can lead to a higher incidence of delayed
union in atypical femoral fractures, prolonged bisphospho-
nate administration requires a great deal of care and drug
holidays.
The incidence of bilateral fractures in this study was as
high as in prior ones: 5 out of 15 cases involved bilateral
femoral fractures in this study [5]. In the cases of atypical
femoral fractures, therefore, it is necessary to carefully
observe the other femur because bisphosphonate administra-
tion may increase the incidence of bilateral femoral fractures
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osteoporotic agent administration may lead to a higher inci-
dence of bilateral fractures [2,9]. No statistically significant
correlation was found between the two factors, probably
because of the small sample. Nonetheless, further research
should be conducted on this issue.
Since incomplete fractures of the other femur can be
healed using conservative treatment in some cases but
develop into complete ones in other cases, the need for pro-
phylactic internal fixation is still controversial. Some re-
searchers suggest performing prophylactic internal fixation
when the patients feel pain in their lower limb and when
periodic x-rays, magnetic resonance imaging (MRI) scans,
and bone scans show that a fracture is imminent [10]. Das De
et al. recommended prophylactic internal fixation when an
atypical incomplete femoral fracture is found along with its
clinical symptoms among the patients administered with
bisphosphonate for a long time [11]. In this study, a unilateral
atypical fracture was followed by an atypical incomplete
fracture on the other side in four out of five cases of bilateral
atypical femoral fractures and prophylactic internal fixation
was performed in three of the four cases because of the
prodromal pain in the other lower limb and impending frac-
ture patterns on x-ray findings. All cases were successfully
treated using preventive intramedullary nailing. It is probably
desirable to perform prophylactic internal fixation when an
atypical incomplete fracture is identified along with its clin-
ical symptoms.
Delayed union or nonunion in femoral fractures can
remarkably increase the treatment duration and medical ex-
penses, lower the quality of life, and lead to poor prognoses. A
bone graft can be effective against nonunion, which occurred
in one out of fifteen cases in this study and was treated through
revision surgery with bone grafting (Fig. 4).
In addition to a bone graft, synthetic parathyroid hormone
agents could reportedly increase the rate of bone unions
among fracture patients and stimulate bone unions among the
patients with nonunions [12e14]. It is believed that para-
thyroid hormone agents can also help shorten the period of
time required for bone union in atypical femoral fractures and
further research should be conducted on this issue.
Atypical femoral fractures are hard to treat and require a
great deal of care. It is necessary to use bisphosphonate both
because it is known that the incidence of atypical femoral
fractures is not high and because bisphosphonate administra-
tion is very effective in preventing osteoporotic fractures.
However, it is necessary to protect against complications in
using bisphosphonate. Further, atypical femoral fractures need
to be treated, taking clinical features into account.
5. Conclusion
Atypical femoral fractures required more time for bone
union than typical ones and prolonged bisphosphonate
administration led to a longer period of time required for bone
union. Because atypical femoral fractures are bilateral ones inmany cases, a unilateral atypical fracture may require
continuous radiographic observation of the other femur.
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